Simulations of Oligomeric Intermediates in Prion Diseases  by Mobley, David L. et al.
Biophysical Journal Volume 85 October 2003 2213–2223 2213
Simulations of Oligomeric Intermediates in Prion Diseases
David L. Mobley, Daniel L. Cox, Rajiv R. P. Singh, Rahul V. Kulkarni, and Alexander Slepoy*
Department of Physics, University of California at Davis, Davis, California; and *Sandia National Laboratories,
Albuquerque, New Mexico
ABSTRACT We extend our previous stochastic cellular automata-based model for two-dimensional (areal) aggregation of
prion proteins on neuronal surfaces. The new anisotropic model allows us to simulate both strong b-sheet and weaker
attachment bonds between proteins. Constraining binding directions allows us to generate aggregate structures with the
hexagonal lattice symmetry found in recently observed in vitro experiments. We argue that these constraints on rules may
correspond to underlying steric constraints on the aggregation process. We ﬁnd that monomer-dominated growth of the areal
aggregate is too slow to account for some observed doubling-time-to-incubation-time ratios inferred from data, and so consider
aggregation dominated by relatively stable but noninfectious oligomeric intermediates. We compare a kinetic theory analysis of
oligomeric aggregation to spatially explicit simulations of the process. We ﬁnd that with suitable rules for misfolding of oligomers,
possibly due to water exclusion by the surrounding aggregate, the resulting oligomeric aggregation model maps onto our
previous monomer aggregation model. Therefore it can produce some of the same attractive features for the description of prion
incubation time data. We propose experiments to test the oligomeric aggregation model.
INTRODUCTION
Prion diseases are a group of neurodegenerative diseases
including bovine spongiform encephalopathy (BSE) in
cattle, scrapie in sheep and goats, chronic wasting disease
in deer and elk, and kuru and Creutzfeldt-Jakob disease
(CJD) in humans. These diseases came to the forefront after
BSE reached epidemic proportions in Great Britain in the
early 1990s, and it was later shown that transmission of BSE
to humans can lead to new variant CJD (vCJD) in humans
(Bruce et al., 1997; Hill et al., 1997; Scott et al., 1999).
Prion diseases are unusual in that they appear to be caused
by infection with some minimal infectious ‘‘seed’’ of
misfolded prion protein, which alone may be able to cause
disease by catalyzing further misfolding and, in many cases,
aggregation of the prion protein. These aggregates are
typically amyloidlike ﬁbrils or amyloid plaques (Caughey,
2000). The infectious agent is unusually hard to eliminate by
various methods including ultraviolet irradiation, suggesting
it contains no nucleic acid and rather only protein, the so-
called ‘‘protein-only’’ hypothesis in prion diseases (Weiss-
mann et al., 2002).
In the case of CJD, a sporadic form of the diseases also
exists, occurring more or less randomly worldwide with an
incidence of about one in a million people per year. It has
been suggested that this incidence is due to the very rare
event of nucleating the minimal infectious seed by chance in
a healthy individual (Come et al., 1993).
Developing an understanding of these diseases is
important because, for one, they are invariably fatal. To
date, no treatment exists. Additionally, it is not yet clear how
large the vCJD epidemic in humans will be; an understand-
ing of the disease process is important to be able to guide the
search for treatment ideas.
In many cases, prion diseases result in large, up-to-
micron-scale plaques in the brains of people and animals
with these diseases. They also involve vacuolization or
spongiform change in the brain due to death of neurons
(Scott et al., 1996). Additionally, the normal form of the
prion protein (known as PrPC) has long been known to
misfold and aggregate in vitro when catalyzed by the
presence of a misfolded prion protein (PrPSc) seed (Come
et al., 1993). Together, these observations have suggested to
some that the aggregation process itself may be important in
these diseases (Come et al., 1993; Masel et al., 1999). It has
also been suggested that the rate-limiting step in aggregation
is nucleation of an appropriate seed, thus the rapid
aggregation in the seeded case described above (Come
et al., 1993).
Another fact which may be important to this issue is that
the prion protein is normally GPI-anchored to the cell
surface. Aggregation in vitro as mentioned above is observed
in solution rather than in the presence of the GPI anchor on
a cell surface, leaving the possibility that the aggregation
process in vivo is different.
Aggregation models developed to explore the aggregation
process in prion disease include one-dimensional, ﬁbrillar
aggregation-and-ﬁssion models (Masel et al., 1999; Slepoy
et al., 2001), since aggregates grown in vitro are typically
seen to be ﬁbrillar. Additionally, our earlier work suggested
that an areal aggregation model could explain certain other
properties of the diseases (Slepoy et al., 2001). By areal
aggregation, we mean two-dimensional aggregation in
a relatively regular array, probably on the cell surface due
to GPI anchoring, in contrast to the one-dimensional, ﬁbril-
lar aggregation observed in vitro, and also in contrast to
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two-dimensional plaques of crossing ﬁbrils which can
be observed in vivo. This earlier model is attractive in that
it can provide a simple explanation for the long lag phase
which is sometimes observed in growth of the amount of
infectious material in the brain. This lag phase of little or
no growth is followed by a doubling phase with a short
characteristic doubling time. Additionally, our earlier model
provides a possible explanation of some of the difference
between infectious and sporadic forms of CJD (Slepoy et al.,
2001). In later work, we used this model to explain and ﬁt
experimental dose incubation curves (Kulkarni et al., 2003).
However, there were drawbacks to the earlier aggregation
model we proposed. First, no such areal aggregates had so far
been observed. Second, the ﬁssioning essential to the model
would involve breaking of strong bonds between the proteins,
probably bonds between b-sheets (Serag et al., 2002).
More recent experimental work found two-dimensional
areal aggregates of prion protein produced during the
puriﬁcation process. These aggregates were examined under
electron microscope and found to consist of trimeric or
hexameric subunits. These subunits are linked together in
a regular array, possibly by their N-terminal sugars or a weak
protein-protein interaction (Wille et al., 2002).
This suggested we should modify our earlier model and
attempt to reproduce this aggregate morphology. We thought
of two basic schemes for growing aggregates of this sort:
1. Growing the aggregate outward, monomer by monomer,
from an initial seed, or
2. Oligomeric intermediates (possibly very ﬂexible and of
unstable shape), which form on their own in solution and
are only catalyzed into stably misfolding in the presence
of an existing misfolded seed.
Some evidence in favor of case 2 has already been
produced. Monomers of yeast prion can form intermediates
if left to stand, which allows aggregation to proceed at an
initial faster rate when catalyzed by addition of a seed (Serio
et al., 2000). Additionally, the conformation-dependent im-
munoassay developed by Safar et al. (2002) detects both
protease-sensitive and protease-resistant PrPSc. In hamster
brains, sensitive PrPSc is observed earlier, followed by
resistant PrPSc. This could correspond to case 2 above, where
the sensitive PrPSc is the intermediates that are not yet stably
misfolded and the resistant PrPSc is stably misfolded inter-
mediates.
Work here has been done to further explore these two
potential modiﬁcations of our earlier model to examine
whether they retain the same features and if additional
insight can be gained.
It is important to note that even if areal aggregation is not
important to the time course of these diseases, the aggregates
observed by Wille and co-workers have already provided
insight into the structure of the misfolded prion protein
(Wille et al., 2002). Theoretical modeling may be able to
place further constraints on the protein or subunit structure
necessary to reproduce these aggregates, and hence provide
valuable information because these aggregates can form,
even if they are not important to the disease progression.
BASICS OF OUR MODEL
Here we explore the two basic schemes suggested above for
growing aggregates like those observed by Wille et al.
(2002). To do so, we use a modiﬁcation of our earlier model.
Therefore a recap of common features of these models is
useful.
These models are stochastic cellular automata models,
meaning that they take place on a lattice with probabilistic
interaction and diffusion rules governing the progression of
the system. In this case, sites on the lattice are either
occupied by individual prion proteins, or water (empty, in
the simulation). The protein form at a site can also vary from
PrPC to PrPSc.
Rules vary depending on the model being explored, but the
basic procedure is the same. For every simulation step, which
represents a small amount of time, we allow proteins and any
aggregates to diffuse a small amount on the lattice (each
object has a probability 1/(size)1/2 of moving one lattice site
in a given step). Then we look at every protein in the lattice
and update its state according to the rules. For example, in our
original model, the conformation of an individual prion
protein is determined solely by its number of neighboring
prion proteins, and this can vary from step to step. After
doing this, we add more normal prion monomers to replace
any that converted to PrPSc. This is due to the assumption that
this process would be taking place in a small area on a cell,
and the normal prion monomers would be added by the cell
or diffuse in from other locations on the cell surface to keep
the monomer concentration relatively constant.
GROWTH VIA MONOMER ADDITION
First, case 1 from above was explored. Simple rules were
developed (Fig. 1) which can reproduce aggregates similar to
those observed by Wille et al. (2002). It is important to note
that although the rules were designed to reproduce such
aggregates, most modiﬁcations of these rules could not do
so. This means that the rules provide some constraints on
the protein-protein interactions necessary to reproduce such
aggregates. Also, for the purposes of this model, we are
assuming the subunits are hexameric, but the corresponding
model for trimeric intermediates is actually much simpler
than this model and will produce similar results. Details of
the algorithm for this model are covered in Fig. 2.
The rules are as follows. The simulation begins with
a single hexagonal subunit consisting of six misfolded
monomers (light gray hexagons in Fig. 1) which stick some
of their residues into an adjacent site, excluding anything
else from occupying that site (black). Healthy monomers
(light gray spheres) can then attach via a sugar-bond or other
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weak protein-protein interaction to this subunit (dark gray
spheres to dark gray hexagons) but only radially outward
from a monomer in the initial hexamer. Additional mono-
mers moving adjacent to the attached monomer can, together
with it, misfold but only if the second monomer does not also
neighbor the original hexamer. Then additional monomers
can attach to this forming hexamer, allowing it to complete.
Repeating this process many times can produce mostly reg-
ular aggregates with some holes, similar to those observed.
The rules are also probabilistic: above, ‘‘can’’ means that
some fraction of the time the event occurs. These prob-
abilities can be changed in the simulation and give different
growth rates, but the same essential features and scaling as
described below.
If this is in fact how these aggregates are forming, we ﬁnd
out about the orientation of monomers within a hexagonal
subunit. We ﬁnd, as mentioned in the discussion of the rules
above, that the N-terminal sugars or attachment sites must
stick radially outward from each monomer in a hexagonal
subunit (Fig. 1 b). This is in agreement with the hexagonal
structure proposed by Wille and co-workers (Wille et al.,
2002). Additionally, we ﬁnd that no such regular aggregates
can be produced unless the monomer attaching to a pre-
viously attached monomer (Fig. 1 c) can only attach if it is
not adjacent to an existing hexamer. This seems to indicate
that the other spaces must be occupied by residues from the
existing hexamer, preventing attachment in those sites.
This model can also reproduce gaps in aggregates as
observed. In this model gaps are due to variations of the
growth rate from average for part of the aggregate, causing
several parts of the aggregate to grow apart and then rejoin
after leaving a gap.
One reason for developing this model was to see if it
would capture the same features of the disease as our original
model. Our original model explained the difference be-
tween the lag phase and the doubling phase by suggesting
that the doubling phase is initiated when aggregates begin
to ﬁssion, then regrow to a certain ﬁssioning size and
break again. Key to this explanation is our result that
aggregation speeds up, so that the time for an aggregate to
double in size from half its ﬁssion size to its ﬁssion size is
much less than the time for it to get from its initial size to
its ﬁssioning size.
To see if this model could produce the same separation of
lag and doubling phases, we examined the aggregate growth
rate as a function of size in this model (Fig. 3) and found it
speeds up only slowly. Naı¨vely, one would expect the
growth rate to be roughly proportional to the square root
of the size, as the growth rate is proportional to the
circumference of the aggregate, which, assuming a circular
aggregate, is 2pr. The size of the aggregate is proportional to
the area, pr2, so the radius is proportional to the square root
of the size and thus the rate proportional to the square root
of the size. To a good approximation, the growth rate ob-
served here is well-ﬁt by an offset plus a term proportional to
(size)1/2, as expected.
In this simple picture, one can calculate the ratio of the
doubling time to the lag time. The lag time is the time to go
from the initial size, say size 0 for simplicity, to size n; the
doubling time from size n/2 to size n. Integrating the rate to
get the times and taking the ratio we ﬁnd tdoub=tlag ¼
1 1= ﬃﬃﬃ2p or ;0.293. This means that this model cannot
produce such a large separation between lag and doubling
times as our earlier model could, at least not without further
modiﬁcation.
This also indicates that if there is a lag phase and if the
difference between it and the doubling phase is due to
acceleration of aggregation, this picture is not sufﬁcient and
FIGURE 1 Simple rules for monomer-by-monomer growth of aggregates like those observed. Some possible rules can be excluded, thus these rules give
insight into how the proteins involved must be interacting with one another. (a) The initial seed consists of six misfolded monomers (light gray hexagons)
surrounding a central region (black) which is occupied by some residues sticking into it from the adjacent six sites. (b) A healthymonomer (light gray sphere) can
move adjacent to a misfolded one and attach via a sugar bond or other weak protein-protein interaction (proteins sugar-bonded are colored dark gray). This
cannot happen if the monomermoves into the site between twomisfolded proteins. (c) Subsequent monomers canmove next to the attached one andmisfold and
begin to form a new hexamer. Residues from the two stick into the black region, preventing anything else from moving there. This cannot happen if the second
monomer is adjacent to the existing hexamer; this would produce irregular aggregates unlike those observed by Wille and co-workers (Wille et al., 2002). (d )
The forming hexamer can grow and ﬁnish via subsequent monomer addition. (e) Continue a–d for a long time, and an aggregate like the one shown can form.
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something more like case 2, growth from intermediates, may
be a better representation of the disease process.
GROWTH VIA INTERMEDIATES
In this case, aggregation is assumed to be the assembly of
independent hexameric intermediates into a larger areal
aggregate. The intermediates themselves are not misfolded
but only misfold, in this model, when they either aggre-
gate with an existing misfolded seed, or come together in
such a way that they can misfold and form a new stable
seed. In this way, the model works essentially just like the
model of Slepoy et al. (2001), except now hexameric inter-
mediates are playing the role of monomers (Fig. 4). As
FIGURE 2 Flow chart of sim-
ulation for monomer addition
model. We typically use P3 ¼
0.2; we tried a variety of differ-
ent values for this and values
near 0.2 seem to produce the
most regular aggregates. We
also typically use PS¼ 0.9. This
is not important and roughly sets
the simulation timescale. Also,
for our statistics, we typically
average[1000 such runs as the
one described here.
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mentioned above, there is some evidence that intermediates
greatly increase aggregation rate in studies of yeast prions, so
this emphasis on the importance of intermediates may be
reasonable.
To be able to map this model back into our old model,
though, we need to know how the intermediate concentration
depends on monomer concentration. And this is not obvious.
So a simulation was developed to explore how the con-
centration of hypothetical hexameric intermediates would
depend on monomer concentration. Again, here we are
assuming the intermediates are hexameric but we can easily
modify the model to accommodate trimers.
To get at the concentration of intermediates, it was as-
sumed that two monomers have a probability P1 of begin-
ning a new hexameric subunit when they come into contact
(see Fig. 5). This new subunit can grow by addition of
monomers when they move into appropriate positions
(changing this probability does not affect the outcome of
the simulation, only the timescale, so it was set to 1).
However, this growth process competes with a ‘‘dissolving’’
process by which a monomer that is part of an intermediate
but only has one neighboring monomer can break off with
a probability P3. Thus the end destiny of any intermediate
that begins is either to form a complete hexameric in-
termediate, in which case it can persist, or to dissolve com-
pletely. Details of the algorithm for this model are shown in
Fig. 6.
This dissolving, or reversibility, was included because it
was not obvious that at low monomer concentrations, one
would expect a reasonable formation rate of intermediates via
this mechanism. It was initially thought that at concentrations
below something on the order of P3, breaking would
dominate and the formation rate of intermediates would be
almost zero. First, the simulation that was developed was
used to examine the dependence of time for intermediate
formation as a function of monomer concentration (Fig. 7). It
was found that at high monomer concentration, the time to
form an intermediate scales between 1/c and 1/c2 (c is
concentration). This is because the likelihood of starting an
intermediate scales as the dimer concentration (1/c2), whereas
the time to add monomers to it scales as 1/c. On the other
hand, at very low monomer concentration, the time
asymptotically approaches 1/c6. This is due to the fact that
at these concentrations, dissolving dominates and it is only in
the very rare event that six monomers are in the same place at
FIGURE 3 Growth rate (change in aggregate size per step) as a function
of size for seeded areal aggregation in the monomer growth model. Growth
rate goes as the square root of the size with an offset, which was as expected
for this model.
FIGURE 4 (a) As in Slepoy’s model (Slepoy et al., 2001), subunits were
healthy monomers (light gray spheres) aggregating with misfolded
monomers (dark gray hexagons); (b), subunits are hexagonal intermediates
(light gray/dark gray) aggregating with misfolded hexagonal structures
(medium gray/dark gray). In both cases, the aggregation process and kinetics
ought to be, and indeed are, similar.
FIGURE 5 Rules for the formation of intermediates. Note that growth and
dissolving compete, so that any intermediate eventually either becomes
a complete, stable hexagon or dissolves back into monomers. (a) Two
monomers have a probability P1 of joining to begin a new intermediate,
which is not yet stably misfolded. Black represents a region blocked by some
of their residues. (b) This can grow by addition of monomers to either
‘‘end.’’ After attaching, the monomer sandwiched between the other two has
two neighbors and is not allowed to break off, whereas the ones with only
one neighbor can. (c) A monomer with only one neighboring monomer has
a probability P3 of breaking off in a given step. This competes with the
growth process. (d ) Continuing addition of monomers can result in a ﬁnished
hexameric intermediate where every monomer has two neighbors and is safe
from breaking off.
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almost the same time that an intermediate can ﬁnish. The
probability of that scales as 1/c6.
It is interesting to note that the beginning of the transition
between high concentration behavior, where most inter-
mediates successfully become complete, and low concen-
tration behavior, where only a lucky few do, begins at
a concentration on the order of the breaking probability, P3.
This suggests that if the strength of bonds between in-
termediates could be weakened somehow, the biological
number of intermediates could be drastically decreased by
pushing biological monomer concentrations into the 1/c6
regime.
The goal, however, was to determine the dependence
of the intermediate concentration on monomer concentra-
tion. This just provided a formation rate, and the functional
form was uncertain. So another sort of result was exam-
ined, wherein we began examining behavior of the system
as a function of time, and measured the number of differ-
ent partial intermediates (two monomers, . . .ﬁve mono-
mers, hexameric intermediates). We ﬁrst examined the case
with no breaking (P3 ¼ 0) to check our results, because
it is relatively easy to work out kinetics in that case. A
sample of one of these plots is shown in Fig. 8, with
symbols as data points and solid lines as approximate
kinetics ﬁts. It is important to note that in this case, and in
the case of nonzero breaking probability, the number of
dimers, trimers, tetramers, and pentamers reaches equilib-
rium relatively quickly and then the hexamer number
begins to grow linearly at a rate equal to the rate of dimer
formation.
FIGURE 6 Flow chart of sim-
ulation for the formation of
intermediates. Note that P1 we
vary for different runs, P2 we
typically set to 1 (it sets the
simulation timescale and is un-
important), and P3 we also vary.
Finished intermediates are re-
moved so that we can run to a
larger number of ﬁnished inter-
mediates without the lattice get-
ting clogged. Here, also, we
typically average [1000 trials
for good statistics.
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Sample results with nonzero breaking are shown in Fig. 9.
These results are qualitatively similar, except the number of
pre-intermediates that persists is much lower. In the high-
breaking limit, the very low level of intermediates dem-
onstrates that either a potential intermediate gets ‘‘lucky’’
and quickly forms an intermediate, or it dissolves back to
monomers, leaving few dimers, trimers, and so on.
The kinetics equations we can write down to describe this
simulation are relatively simple. With rnm as the rate constant
for forming m-mers from n-mers, and bnm as the rate of
breaking n-mers into m-mers plus monomers, we can write:
½c1 ¼ c (1)
d½c2
dt
¼ r12½c12  r23½c1½c2  b21½c21 b32½c3 (2)
d½c3
dt
¼ r23½c1½c2  r34½c1½c3  b32½c31 b43½c4 (3)
d½c4
dt
¼ r34½c1½c3  r45½c1½c4  b43½c41 b54½c5 (4)
d½c5
dt
¼ r45½c1½c4  r56½c1½c5  b54½c5 (5)
d½c6
dt
¼ r56½c1½c5: (6)
Since we know that the hexamer number grows linearly at
steady state and all of the other concentrations are un-
changing, we can greatly simplify the above kinetics by
looking at the steady state only. We can work backward from
the steady-state behavior of the hexamers to ﬁnd the
dependence of the steady-state rate of hexamer formation
on the different kinetic parameters and ultimately on the
monomer concentration.
This straightforward kinetics analysis produces the
equilibrium result
m ¼ r12c
2
11
b21
r23c
11
b32
r34c
11
b43
r45c
11
b54
r56c
    ; (7)
where m is the slope at equilibrium of the hexamer formation
rate.
The constants in our simple result for m, above, can be
measured from our simulation. However, our simulation
does not necessarily reproduce what these constants would
FIGURE 7 Simulation steps (time) to form a hexameric intermediate as
a function of monomer concentration. Log-log scale. Note the broad
transition to dissolving-dominated behavior at low concentration. The
transition actually continues to even lower concentration than can be seen
here. At very low concentration the time eventually scales as 1/c6. Standard
deviations fall within the size of the data points on this plot.
FIGURE 8 Number of each size as a function of time (simulation steps),
with zero breaking. Note that, at long times, intermediates reach equilibrium
and the hexamer number begins growing linearly with time. Points are
simulation data points; solid lines (mostly overlapping points) are
approximate kinetics results.
FIGURE 9 Number of each size as a function of time (simulation steps)
with nonzero breaking. Compare to Fig. 6; note that the number of
intermediates reaches equilibrium faster and at smaller numbers, but that the
hexamer number still grows linearly at long times.
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be in a biological system. So it is difﬁcult to say exactly what
the rate of intermediate formation, m, would be in a real
system. However, it is nevertheless useful to know the
functional form of its dependence on the monomer con-
centration.
The result that the hexamer number begins growing
linearly eventually is independent of monomer concentra-
tion. This is important because it means some hexamers can
form given these simple rules even if breaking dominates.
Given that result, it seems safe to assume that if hexameric
intermediates are stable, some will form in biological
systems.
In our model, the hexamer number grows linearly
indeﬁnitely, which is obviously unrealistic biologically.
The reason for this is that we include no mechanism to
remove ﬁnished hexamers. Realistically, they would be
cleared from the body somehow. They could be endocytosed
from the cell surface and degraded via the proteasome
mechanism or some other pathway. Additionally, any
hexamers being taken up into aggregates would reduce this
number. Regardless, realistically the number should stabilize
at some ﬁxed value determined by the balance of the
clearance rate and the formation rate.
With the result that some hexamers form even at low
monomer concentrations (and more would form if they are
trimers), a model was developed where now hexameric
intermediates occupy a single cell on the lattice (equiva-
lently, these could be trimeric intermediates). This model,
described below, largely maintains the same attractive
features of the original, showing that if areal aggregation is
the explanation for these features, as we suggested, this
aggregation could be of hexameric intermediates.
Part of our basis for this model is the observation that the
intermediates are not yet stably misfolded since formation of
intermediates in studies of yeast prions does not lead to
a change in circular dichroism results; it is only when they
aggregate with a seed that they stably misfold (Serio et al.,
2000). This also is justiﬁed by observing that if intermediates
were stably misfolded, they could act as seeds on their own,
without the necessity of an external seed initiating the
infection, and thus there would be no difference between
sporadic and infectious CJD. Therefore, for aggregates
consisting of misfolded oligomers like those observed by
Wille et al. (2002), intermediate misfolding must be
catalyzed by existing aggregates or few-hexamer misfolded
oligomers. We hypothesize that the mechanism for this is
intermediates forming bonds to an existing seed. When
solvent is excluded locally around these oligomers and their
neighbors include a misfolded oligomer or aggregate, they
misfold. The important point is that it is solvent exclusion
around an intermediate that can cause it to misfold, making
this a very rare sporadic event. But a misfolded seed can help
this process by providing a place where intermediates bond,
helping the solvent-exclusion process. These rules make this
model essentially identical in terms of kinetics to our original
model. Details of the algorithm for this model and mapping
are shown in Fig. 10.
However, from our old model we estimated the sporadic
form of the disease could have a peak at;1000 years, given
a biological concentration of 103%. In our new model we
ﬁnd that it is very difﬁcult to estimate this number as the
scaling of the time as a function of monomer concentration is
complicated. It was hoped that this model would give a result
for the onset of sporadic disease that could be compared with
the time for onset of the infectious form to see if the results
were consistent with the roughly 1-in-106 incidence of
sporadic CJD that we earlier pointed out. Unfortunately, it is
difﬁcult for our model to give a concrete answer at this time
as the answer depends too much on the value of the
biological monomer concentration. We do ﬁnd, however,
that the power law used previously to scale the sporadic data,
c3, is a lower bound on the separation. That is, the actual
exponent should be larger, meaning that we previously
underestimated the separation of timescales. Thus although
we cannot say exactly what the separation of timescales here
will be, we can say that it will be greater than the two orders
of magnitude that we previously estimated.
This work suggests that a model like our earlier one,
modiﬁed to involve areal aggregation of hexameric or
trimeric intermediates, could maintain the same attractive
features of our earlier model in explaining certain aspects of
the diseases. However, without precise knowledge of the
biological monomer concentration and a way to measure
relevant rate constants, it is difﬁcult to make numerical
predictions from this model.
DISCUSSION
Our work has shown that both in the case of monomer
addition to a seed, and in the case of growth via in-
termediates, it is possible to produce aggregates like those
observed by Wille et al. (2002). This leaves the question of
how such aggregates actually grew. If areal aggregation is
the cause, or part of the cause, of the difference between lag
and doubling times, as suggested by Slepoy et al. (2001),
then our work suggests that intermediates are already present
in vivo before aggregation.
Our work has also shown that a model can be developed
which, with suitable parameters, can reproduce areal ag-
gregates like those actually observed while maintaining the
same features of our original model.
Whether or not areal aggregation is actually important in
these diseases, we can gain insight from this model. If the
aggregates observed are growing via monomer addition, we
gain some constraints on the structure simply from our rules.
On the other hand, if intermediates are important to
aggregation, then our results indicate the intermediate
concentration can be quite important. At high intermediate
concentrations, intermediates form relatively fast. However,
at low intermediate concentrations, intermediate formation
2220 Mobley et al.
Biophysical Journal 85(4) 2213–2223
timescales as 1/c6. This result is exciting because it suggests
the intermediates as a target to prevent aggregation. Simply
reducing the monomer concentration by a factor of 2 would
decrease the number of intermediates by a factor of 26 or 64.
Within our model, this would certainly increase the aggrega-
tion time, and thus slow down the disease, by at least the
same factor. For a disease which can typically incubate for
years, this obviously would be a great advantage.
In this case, the location of the transition between low
concentration behavior and high concentration behavior is,
roughly speaking, set by the probability of monomers
breaking off from an intermediate before it becomes a sta-
FIGURE 10 Flow chart for
simulation mapping back into
our original model. Here we
basically have free monomers
(fMs), attached monomers that
are not yet stably misfolded
(aM), and monomers that have
stably misfolded and aggregated
(H). We have some choice of a
parameter, Qbc ¼ m. This model
will capture the features of our
original model for m between 3
and 6, and the simulation will
proceed in exactly the same
way. We compute Nbc, the bond
coordination number, with Nbc
¼ nfM 1 naM 1 (m  1) 3 nH,
where the n is the number of
neighboring fMs, and so on. Nhc,
the ‘‘hardening’’ or aggregating
coordination number, is given
by Nhc ¼ nfM 1 naM 1 nH. We
refer to Qbc as the bonding
critical coordination number and
Qhc as the ‘‘hardening’’ critical
coordination number.
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ble hexamer. Thus if this probability could be increased
slightly—that is, the bonds between monomers could be
weakened slightly—it would have the result described
above. This could provide an explanation for one experi-
mental observation. Humans have a methionine/valine
polymorphism at codon 129 of the gene for the prion
protein. To date, everyone affected by vCJD has been
methionine/methionine homozygous. This effect was also
seen in the prion disease Kuru, where the methionine/
methionine genotype was associated with increased sus-
ceptibility and the shortest incubation time (Goldfarb,
2002). If replacing methionine with valine weakened the
monomer-monomer bonds within a forming intermediate
and reduced intermediate concentration, this could have
exactly the effect described above. This is, however, highly
speculative, but as Wille et al. (2002) reﬁne their model of
the oligomer structures, it will be interesting to see if this
residue falls in the region important to bonding between
monomers.
In all, our work shows that our earlier model can be
extended to produce aggregates like those observed in vitro
while still maintaining its attractive features. Our work also
suggests possible mechanisms for formation of these
aggregates. If the aggregates form by monomer addition, it
constrains protein structure. If they form by addition of
intermediates, it highlights the importance of bonds within
the intermediates as a target for possible treatment strategies.
Our model suggests that an experiment to measure the
biological intermediate concentration, if there is such
a concentration, would be very useful. That would indicate
whether such intermediates are present at a high enough
concentration to be important biologically. Additionally, this
work suggests that experimentalists should check and see
whether reasonably-sized aggregates of prion protein can be
found in vivo on the cell surface. This conﬁnement to the cell
surface conceivably could make the difference between the
one-dimensional ﬁbrillar aggregates typically observed in
vitro and two-dimensional areal aggregates like those
suggested by the model of Slepoy et al. (2001). Direct
measurements, or detailed simulations, giving the strengths
of b-bonds between monomers compared to bonds between
subunits would be very useful.
One simple way to experimentally discern between
growth via monomers or intermediates may be to look at
high resolution at the boundary of actual areal aggregates. If
growth is by monomers, aggregates will form with mono-
mer-scale roughness at their boundaries (Fig. 1 e) while if
growth is by intermediates, there will be no such roughness
(Fig. 4 b). Experimentally, the absence of such roughness
would not prove the growth via intermediate hypothesis
because incomplete oligomers at the edge of the aggregate
could be removed in the puriﬁcation process, possibly by
proteinase K digestion. However, the presence of such
roughness would certainly suggest that monomer growth is
important.
A more general scheme for experimentally testing the
possible role of intermediates and estimating their concen-
tration is via spin labeling (Hubbell et al., 1998; Columbus
and Hubbell, 2002). Brieﬂy, a small molecule with a free
spin can preferentially react and attach to cysteine residues
in proteins. Frequently, these residues are moved around
a protein via mutagenesis to then map out structures, but for
these purposes a less reﬁned approach is required. Since the
PrP protein already possesses cysteine residues at the
position of the disulﬁde bond, the spin labels can attach
there (and will not disrupt the disulﬁde bond). Then the spin-
spin interactions will produce a different characteristic
spectrum for monomers, incomplete intermediates, and
complete intermediates, in particular, with a progressive
broadening upon moving from monomers to complete
intermediates. Since the spins can have interactions with
other spins within a 3-nm sphere, we do not doubt that the
broadening will be observable. Of course, since the spin
labels will react with any cysteines present, it is important
to carry this out ﬁrst by in vitro aggregation experiments
with puriﬁed prion extracts. This will help to identify
the conditions which can lead to areal aggregation as
observed by Wille et al. (2000), and serve as an existence
proof at least for signiﬁcant oligomeric intermediate con-
centrations.
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